Novo Nordisk ADR (NYSE:NVO) finished Friday with a subtraction of -$0.58 to close at $90.94, a downside of -0.63 percent. An average of 3,142,720 shares of common stock have been traded in the last five days. There was a fall of -$0.36 in the past week, and it reached a new high 55 times over the past 12 months. The last 20 days have seen an average of 4,451,245 shares traded, while the 50-day average volume stands at 3,971,634.
NVO stock has decreased by -3.29% in the last month. The company shares reached their 1-month lowest point of $90.40 on 09/25/23. With the stock rallying to its 52-week high on 09/11/23, shares of the company touched a low of $49.78 and a high of $100.88 in 52 weeks. It has reached a new high 31 times so far this year and achieved 34.39% or $23.27 in price. In spite of this, the price is down -9.85% from the 52-week high.
Valuation Metrics
Novo Nordisk ADR (NVO) has a trailing price-to-earnings (P/E) ratio of 21.60. The stock’s beta is 0.44. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.45, the price-to-book (PB) ratio at 53.68, and the price-to-cash flow ratio at 15.53.
The company has a payout ratio of 36.20%. The company’s most recent quarterly dividend payment was $0.2209 a share, representing a down of -25.67% from $0.2972 last year. Its latest decrease dividend $0.0763 reported on Thursday August 10 2023.
Financial Health
The quick ratio of Novo Nordisk ADR for the three months ended June 29 was 0.70, and the current ratio was 0.88, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.21 and a total debt to equity ratio of 0.28 for the quarter ending June 29. Its gross profit as reported stood at $21.03 billion compared to revenue of $25.06 billion.
Earnings Surprise
The analyst consensus anticipated Novo Nordisk ADR’s latest quarter earnings to come in at $0.62 per share, but it turned out to be $0.61, a -1.60% surprise. For the quarter, EBITDA amounted to $3.81 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Novo Nordisk ADR (NVO) price momentum. RSI 9-day as of the close on 29 September was 36.03%, suggesting the stock is Neutral, with historical volatility in this time frame at 20.80%.
As of today, NVO’s price is $91.42 -0.39% or -$0.36 from its 5-day moving average. NVO is currently trading -2.01% lower than its 20-day SMA and +7.98% higher than its 100-day SMA. However, the stock’s current price level is +10.58% above the SMA50 and +40.11% above the SMA200.
The stochastic %K and %D were 9.83% and 10.94%, respectively, and the average true range (ATR) was 1.97. With the 14-day stochastic at 6.40% and the average true range at 2.02, the RSI (14) stands at 43.64%. The stock has reached -0.61 on the 9-day MACD Oscillator while the 14-day reading was at -2.01.
Analyst Ratings
HSBC Securities launched coverage on Novo Nordisk ADR (NYSE: NVO) in its analyst report released on July 14, 2023. The firm assigned the stock a Buy rating. The consensus rating for Novo Nordisk ADR (NVO) among analysts is Overweight. According to current brokerage recommendations, 4 brokerage firms advise that investors sell NVO, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 15 others rate it as a “buy”.
What is NVO’s price target for the next 12 months?
Analysts predict a range of price targets between $102.19 and $235.00, with a median target of $205.37. Taking a look at these predictions, the average price target given by analysts for Novo Nordisk ADR (NVO) stock is $192.24.
